However, no cutoff value for ACTH has been determined that accurately predicts pituitary tumor progression; thus, ACTH may be an unreliable predictor of tumor growth in patients with CD, especially if levels have not yet stabilized after the expected increase following osilodrostat initiation [24, 48]. This evidence concerns the gene POMC and neoplasm.